# OneSpaWorld

Type: Company (OSW)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/onespaworld
Canonical HTML page: https://getbiobrief.com/entity/onespaworld

## Recent coverage (1 stories)

### Halozyme Revenue Beats Estimates Amidst Massive $2.44 EPS Miss
2026-02-19 04:10:57 · Sentiment: Negative · Impact: 6/10 · Sources: 3

Halozyme Therapeutics reported a strong revenue beat of $451 million for the fourth quarter, driven by its ENHANZE platform royalties, yet surprised investors with a significant non-GAAP EPS miss of $2.44. The discrepancy suggests substantial one-time charges or strategic shifts that contrast with the company's robust top-line growth.
Full story: https://getbiobrief.com/story/halozyme-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.